BRAF and colorectal neoplasm: Whereas, in a previous study we derived LRs for colorectal tumour MSI and BRAF V600E status using a large and well-characterised dataset (where testing for germline alterations was performed on a random subset of MSS tumours), and applied them carefully considering issues relating to ascertainment bias [37].